Predictors of Outcome in Refractory Status Epilepticus
Overview
Affiliations
Objective: To further characterize the demographics, outcomes, and prognostic factors for refractory status epilepticus (RSE).
Design: Retrospective analysis of all the episodes of RSE treated between January 1, 1999, and August 30, 2011.
Setting: Neurointensive care unit within a tertiary referral center, Mayo Clinic, Rochester, Minnesota.
Patients: Refractory status epilepticus was defined as generalized convulsive or nonconvulsive status epilepticus (SE) that continued despite initial first- and second-line therapies. Exclusion criteria were aged younger than 18 years, anoxic/myoclonic SE, psychogenic SE, simple partial SE, and absence SE.
Main Outcome Measures: Functional outcome was defined by modified Rankin scale (mRS) dichotomized into good (mRS, 0-3) and poor (mRS, 4-6). Functional decline was defined as a change in mRS greater than 1 from hospital admission to discharge.
Results: We identified 63 consecutive episodes of non-anoxic RSE in 54 patients. Anesthetic agents were used in 55 episodes (87.30%), and duration of drug-induced coma was (mean [SD]) 11.0 (17.9) days. In-hospital mortality was 31.75% (20 of 63 episodes). Poor functional outcome at discharge occurred in 48 of 63 episodes (76.19%). Hospital length of stay was (mean [SD]) 27.7 (37.3) days. Duration of drug-induced coma (P=.03), arrhythmias requiring intervention (P=.01), and pneumonia (P=.01) were associated with poor functional outcome. Prolonged mechanical ventilation was associated with mortality (P=.04). Seizure control without suppression-burst or isoelectric electroencephalogram predicted good functional recovery (P=.01). Age, history of epilepsy, previous SE, type of SE, and anesthetic drug used were not associated with functional outcome.
Conclusions: Three-quarters of patients with RSE have a poor outcome. Achieving control of the SE without requiring prolonged drug-induced coma or severe electroencephalographic suppression portends better prognosis.
Niazi F, Han A, Stamm L, Shlobin N, Korman C, Hoang T Front Neurol. 2024; 15:1403266.
PMID: 38863514 PMC: 11165020. DOI: 10.3389/fneur.2024.1403266.
Luo Q, Lai R, Su M, Wu Z, Feng H, Zhou H Front Mol Neurosci. 2024; 17:1360949.
PMID: 38699485 PMC: 11064924. DOI: 10.3389/fnmol.2024.1360949.
Mortality, and life expectancy in Epilepsy and Status epilepticus-current trends and future aspects.
Trinka E, Rainer L, Granbichler C, Zimmermann G, Leitinger M Front Epidemiol. 2024; 3:1081757.
PMID: 38455899 PMC: 10910932. DOI: 10.3389/fepid.2023.1081757.
Cardiac Abnormalities in Refractory Status Epilepticus-an Exploratory Study.
Saroha D, Panda S, Deora S, Mohammed S J Epilepsy Res. 2024; 13(2):42-50.
PMID: 38223358 PMC: 10783967. DOI: 10.14581/jer.23007.
Status epilepticus in the ICU.
Rossetti A, Claassen J, Gaspard N Intensive Care Med. 2023; 50(1):1-16.
PMID: 38117319 DOI: 10.1007/s00134-023-07263-w.